Bicyclic heterocycles as FGFR4 inhibitors
View Patent ↗The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR4 enzyme and are useful in the treatment of FGFR4-associated diseases such as cancer.
1. A compound which is N- {[2′-(2, 6-difluoro-3,5-dimethoxyphenyl)-3′-oxo-2′, 3′-dihydro- 1′H-Spiro [cyclopropane-1, 4′-[2,7]naphthyridin]-6′-yl]methyl} acrylamide, or a pharmaceutically acceptable salt thereof.
2. A compound which is N-((2′-(2, 6-difluoro-3,5-dimethoxyphenyl)-3′-oxo-2′, 3′-dihydro-1′H-spiro [cyclopentane-1,4′-[2,7]naphthyridine]-6′-yl)methyl)acrylamide, or a pharmaceutically acceptable salt thereof.
3. A compound which is N-{[2′-(2,6-difluoro-3,5-dimethoxyphenyl)-3′-oxo-2′,3′-dihydro-1′H-spiro[cyclopropane-1,4′-[2,7]naphthyridin]-6′-yl]methyl}acrylamide.
4. A compound which is N-((2′-(2,6-difluoro-3,5-dimethoxyphenyl)-3′-oxo-2′,3′-dihydro-1′H-spiro[cyclopentane-1,4′-[2,7]naphthyridine]-6′-yl)methyl)acrylamide.
5. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.
6. A pharmaceutical composition comprising a compound of claim 3 and a pharmaceutically acceptable carrier or excipient.
7. A pharmaceutical composition comprising a compound of claim 2 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.
8. A pharmaceutical composition comprising a compound of claim 4 and a pharmaceutically acceptable carrier or excipient.